Psychedelics stories

Jul 26, 2026

Phase 2 Clinical Trial Shows THC-CBD Combination Rapidly Reduces Agitation in Advanced Dementia Patients

The LiBBY clinical trial found that a combination of CBD and THC rapidly and significantly reduced agitation in hospice-eligible dementia patients, with nearly 90% of participants showing behavioral improvement in the nationwide study.

Jul 26, 20263 sources

Top claims

▪At Week 2, participants receiving the THC/CBD formulation showed a 6.27-point greater reduction in agitation scores on the Cohen-Mansfield Agitation Inventory than those receiving placebo.
▪More than one-third of people with dementia continue to experience agitation despite off-label treatment with benzodiazepines, opioids, and antipsychotics.
▪The LiBBY trial was a 12-week, multicenter study conducted across 10 U.S. sites, primarily funded by the National Institute on Aging.

Subtopics

Addiction and Harm Reduction1 Age related cognitive decline1 Alzheimer’s & dementia1 Drug Approval and Clinical Trials1 Mental health1 Mental health1 Psychedelic clinical research & trials1

Related timelines